Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1971 2
1972 1
1975 3
1977 1
1983 2
1986 1
1988 2
1989 3
1990 1
1992 2
1994 2
1996 1
1999 2
2002 2
2003 1
2004 2
2005 2
2006 8
2007 13
2008 9
2009 7
2010 7
2011 8
2012 14
2013 11
2014 6
2015 8
2016 10
2017 17
2018 16
2019 16
2020 16
2021 20
2022 26
2023 31
2024 35
2025 40
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m …
METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less tha …
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R; EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2025 Feb 20;392(8):777-787. doi: 10.1056/NEJMoa2409183. Epub 2024 Oct 25. N Engl J Med. 2025. PMID: 39453837 Free PMC article. Clinical Trial.
All the patients had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area or an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (wi …
All the patients had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of bo …
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.
Prespecified subgroups of eGFR included 2282 (34.5%) participants with an eGFR of less than 30 mL/min per 1.73 m(2), 2928 (44.3%) with an eGFR of 30 to less than 45 mL/min per 1.73 m(2), and 1399 (21.2%) with an eGFR 45 mL/min per 1.73 m(2) or higher. ...Over …
Prespecified subgroups of eGFR included 2282 (34.5%) participants with an eGFR of less than 30 mL/min per 1.73 m(2), 2928 (44.3%) wit …
Design of protein-binding proteins from the target structure alone.
Cao L, Coventry B, Goreshnik I, Huang B, Sheffler W, Park JS, Jude KM, Marković I, Kadam RU, Verschueren KHG, Verstraete K, Walsh STR, Bennett N, Phal A, Yang A, Kozodoy L, DeWitt M, Picton L, Miller L, Strauch EM, DeBouver ND, Pires A, Bera AK, Halabiya S, Hammerson B, Yang W, Bernard S, Stewart L, Wilson IA, Ruohola-Baker H, Schlessinger J, Lee S, Savvides SN, Garcia KC, Baker D. Cao L, et al. Nature. 2022 May;605(7910):551-560. doi: 10.1038/s41586-022-04654-9. Epub 2022 Mar 24. Nature. 2022. PMID: 35332283 Free PMC article.
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Free PMC article. Clinical Trial.
Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1.73 m(2), or 45 to less than 90 mL/min per 1.73 m(2) with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. ...The between-g …
Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1.73 m(2), or 45 to les …
Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.
Coleman AE, Creevy KE, Anderson R, Reed MJ, Fajt VR, Aicher KM, Atiee G, Barnett BG, Baumwart RD, Boudreau B, Cunningham SM, Dunbar MD, Ditzler B, Ferguson AM, Forsyth KK, Gambino AN, Gordon SG, Hammond HK, Holland SN, Iannaccone MK, Illing K, Kadotani S, Knowles SA, MacLean EL, Maran BA, Markovic LE, McGrath S, Melvin RL, Mueller MS, Nelson OL, Olby NJ, Pancotto TE, Parsley E, Potter BM, Prescott JO, Saunders AB, Sawyer HM, Scansen BA, Schmid SM, Smith CC, Tjostheim SS, Tolbert MK, Tropf MA, Visser LC, Ward JL, Wesselowski SR, Windsor RC, Yang VK, Ruple A, Promislow DEL, Kaeberlein M; Dog Aging Project Consortium. Coleman AE, et al. Geroscience. 2025 Jun;47(3):2851-2877. doi: 10.1007/s11357-024-01484-7. Epub 2025 Feb 14. Geroscience. 2025. PMID: 39951177 Free PMC article.
Cell types of origin of the cell-free transcriptome.
Vorperian SK, Moufarrej MN; Tabula Sapiens Consortium; Quake SR. Vorperian SK, et al. Nat Biotechnol. 2022 Jun;40(6):855-861. doi: 10.1038/s41587-021-01188-9. Epub 2022 Feb 7. Nat Biotechnol. 2022. PMID: 35132263 Free PMC article.
321 results